Related Experiment Video
Updated: Mar 17, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model
Suman Suman1, Trinath P Das1, Jim Moselhy1
1Department of Urology, University of Louisville, KY, USA.
Abstract:
We previously reported that withaferin A (WA), a natural compound, deters prostate cancer by inhibiting AKT while inducing apoptosis. In the current study, we examined its chemopreventive efficacy against carcinogenesis in the prostate using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Two distinct sets of experiments were conducted. To determine whether WA delays tumor progression, it was given before cancer onset, at week 6, and until week 44. To determine its effect after the onset of prostate cancer, it was given from weeks 12 to 35. In both strategies, oral administration of WA effectively suppressed tumor burden when compared to vehicle-treated animals. No toxicity was seen in treated animals at gross pathological examination. Western blot analysis and immunohistochemistry of tumor sections revealed that in TRAMP controls, AKT and pAKT were highly expressed while nuclear FOXO3a and Par-4 were downregulated. On the contrary, treated mice showed inhibition of AKT signaling and activation of FOX03a-Par-4-induced cell death. They also displayed inhibition of mesenchymal markers such as β-catenin, vimentin, and snail as well as upregulation of E-cadherin. Because expressions of the angiogenic markers factor VIII and retic were downregulated, an anti-angiogenic role of WA is suggested. Overall, our results suggest that WA could be a promising anti-cancer agent that effectively inhibits carcinogenesis of the prostate.
Insights
Withaferin A (WA) effectively combats prostate cancer by inhibiting AKT signaling and promoting apoptosis. This natural compound suppressed tumor growth in mice without observable toxicity, suggesting its potential as a chemopreventive agent.
Area of Science:
- Oncology
- Natural Products Chemistry
- Molecular Biology
Background:
- Prostate cancer remains a significant health concern globally.
- Withaferin A (WA), a natural compound, has shown potential in inhibiting cancer cell growth.
- The precise mechanisms and chemopreventive efficacy of WA in prostate cancer require further investigation.
Purpose of the Study:
- To evaluate the chemopreventive efficacy of Withaferin A (WA) against prostate cancer using the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
- To investigate the effects of WA on tumor progression, signaling pathways, and angiogenesis in prostate cancer.
- To assess the safety and tolerability of WA in the TRAMP model.
Main Methods:
- Oral administration of WA to TRAMP mice at different stages of cancer development (preventive and therapeutic settings).
- Assessment of tumor burden, gross pathology, and toxicity.
- Western blot analysis and immunohistochemistry to evaluate signaling pathways (AKT, FOXO3a, Par-4), epithelial-mesenchymal transition (EMT) markers (β-catenin, vimentin, snail, E-cadherin), and angiogenic markers (Factor VIII, retic).
Main Results:
- WA administration significantly suppressed tumor burden in both preventive and therapeutic settings compared to vehicle controls.
- WA treatment led to inhibition of AKT signaling and activation of FOXO3a-Par-4-induced apoptosis.
- WA suppressed mesenchymal markers and upregulated E-cadherin, suggesting inhibition of EMT. Downregulation of angiogenic markers indicated an anti-angiogenic effect.
Conclusions:
- Withaferin A demonstrates significant chemopreventive and therapeutic potential against prostate cancer in the TRAMP model.
- WA effectively inhibits prostate cancer progression by modulating key signaling pathways involved in cell survival, apoptosis, and EMT.
- WA exhibits anti-angiogenic properties and is well-tolerated, positioning it as a promising natural agent for prostate cancer treatment and prevention.
